Ventricular Tachycardia in Structural Heart Disease

Area of Science:

• Cardiology
• Electrophysiology
• Internal Medicine

Background:

• Structural heart disease (SHD) poses a significant risk for ventricular tachycardia (VT), a challenging clinical management problem.
• Coronary artery disease with myocardial infarction (MI) is the most frequent cause of SHD-associated VT, primarily due to scar-mediated reentry.
• Other conditions like cardiomyopathies and congenital heart disease also contribute to VT in SHD.

Purpose of the Study:

• To review current therapeutic strategies for managing ventricular tachycardia in patients with structural heart disease.
• To highlight the importance of accurate diagnosis and mechanism identification for guiding treatment decisions.
• To discuss the role and limitations of antiarrhythmic drugs and catheter ablation.

Main Methods:

• Review of existing literature on ventricular tachycardia management in structural heart disease.
• Analysis of diagnostic approaches including patient history, ECG, and imaging.
• Evaluation of therapeutic options such as antiarrhythmic drugs and catheter ablation.

Main Results:

• No single treatment guarantees perfect results; combination therapy is often necessary for effective VT control.
• Accurate diagnosis and localization of VT origin are crucial for successful catheter ablation.
• Antiarrhythmic drugs may reduce VT burden but do not improve mortality and can worsen heart failure.

Conclusions:

• Effective management of VT in SHD necessitates a comprehensive approach integrating diagnostic findings with therapeutic interventions.
• Catheter ablation is a key option when indicated, guided by precise arrhythmia localization.
• Careful consideration of antiarrhythmic drug risks, particularly negative inotropic effects, is essential.